433 related articles for article (PubMed ID: 33031833)
1. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
de Vries E; Bolier R; Goet J; Parés A; Verbeek J; de Vree M; Drenth J; van Erpecum K; van Nieuwkerk K; van der Heide F; Mostafavi N; Helder J; Ponsioen C; Oude Elferink R; van Buuren H; Beuers U;
Gastroenterology; 2021 Feb; 160(3):734-743.e6. PubMed ID: 33031833
[TBL] [Abstract][Full Text] [Related]
2. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.
Bolier R; de Vries ES; Parés A; Helder J; Kemper EM; Zwinderman K; Elferink RPO; Beuers U;
Trials; 2017 May; 18(1):230. PubMed ID: 28535810
[TBL] [Abstract][Full Text] [Related]
3. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Thompson D; Richards D; Storey J; Dukes GE; Corrigan M; Oude Elferink RP; Beuers U; Hirschfield GM; Jones DE
Lancet; 2017 Mar; 389(10074):1114-1123. PubMed ID: 28187915
[TBL] [Abstract][Full Text] [Related]
4. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis.
Kremer AE; Mayo MJ; Hirschfield G; Levy C; Bowlus CL; Jones DE; Steinberg A; McWherter CA; Choi YJ
Liver Int; 2022 Jan; 42(1):112-123. PubMed ID: 34403559
[TBL] [Abstract][Full Text] [Related]
5. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
Corpechot C; Chazouillères O; Rousseau A; Le Gruyer A; Habersetzer F; Mathurin P; Goria O; Potier P; Minello A; Silvain C; Abergel A; Debette-Gratien M; Larrey D; Roux O; Bronowicki JP; Boursier J; de Ledinghen V; Heurgue-Berlot A; Nguyen-Khac E; Zoulim F; Ollivier-Hourmand I; Zarski JP; Nkontchou G; Lemoinne S; Humbert L; Rainteau D; Lefèvre G; de Chaisemartin L; Chollet-Martin S; Gaouar F; Admane FH; Simon T; Poupon R
N Engl J Med; 2018 Jun; 378(23):2171-2181. PubMed ID: 29874528
[TBL] [Abstract][Full Text] [Related]
6. Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review.
Smith HT; de Souza AR; Thompson AH; McLaughlin MM; Dever JJ; Myers JA; Chen JV
Dig Dis Sci; 2023 Jun; 68(6):2710-2730. PubMed ID: 36933112
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kowdley KV; Bowlus CL; Levy C; Akarca US; Alvares-da-Silva MR; Andreone P; Arrese M; Corpechot C; Francque SM; Heneghan MA; Invernizzi P; Jones D; Kruger FC; Lawitz E; Mayo MJ; Shiffman ML; Swain MG; Valera JM; Vargas V; Vierling JM; Villamil A; Addy C; Dietrich J; Germain JM; Mazain S; Rafailovic D; Taddé B; Miller B; Shu J; Zein CO; Schattenberg JM; ;
N Engl J Med; 2024 Feb; 390(9):795-805. PubMed ID: 37962077
[TBL] [Abstract][Full Text] [Related]
8. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial.
Kuiper EM; van Erpecum KJ; Beuers U; Hansen BE; Thio HB; de Man RA; Janssen HL; van Buuren HR
Hepatology; 2010 Oct; 52(4):1334-40. PubMed ID: 20683930
[TBL] [Abstract][Full Text] [Related]
9. Fibrates for the treatment of pruritus in primary biliary cholangitis: a systematic review and meta-analysis.
Shen N; Pan J; Miao H; Zhang H; Xing L; Yu X
Ann Palliat Med; 2021 Jul; 10(7):7697-7705. PubMed ID: 34353058
[TBL] [Abstract][Full Text] [Related]
10. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
Schattenberg JM; Pares A; Kowdley KV; Heneghan MA; Caldwell S; Pratt D; Bonder A; Hirschfield GM; Levy C; Vierling J; Jones D; Tailleux A; Staels B; Megnien S; Hanf R; Magrez D; Birman P; Luketic V
J Hepatol; 2021 Jun; 74(6):1344-1354. PubMed ID: 33484775
[TBL] [Abstract][Full Text] [Related]
11. GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus.
Levy C; Kendrick S; Bowlus CL; Tanaka A; Jones D; Kremer AE; Mayo MJ; Haque N; von Maltzahn R; Allinder M; Swift B; McLaughlin MM; Hirschfield GM;
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1902-1912.e13. PubMed ID: 36343847
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
[TBL] [Abstract][Full Text] [Related]
13. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Reig A; Sesé P; Parés A
Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
[TBL] [Abstract][Full Text] [Related]
14. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
Hirschfield GM; Bowlus CL; Mayo MJ; Kremer AE; Vierling JM; Kowdley KV; Levy C; Villamil A; Ladrón de Guevara Cetina AL; Janczewska E; Zigmond E; Jeong SH; Yilmaz Y; Kallis Y; Corpechot C; Buggisch P; Invernizzi P; Londoño Hurtado MC; Bergheanu S; Yang K; Choi YJ; Crittenden DB; McWherter CA;
N Engl J Med; 2024 Feb; 390(9):783-794. PubMed ID: 38381664
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis and Management of Pruritus in PBC and PSC.
Kremer AE; Namer B; Bolier R; Fischer MJ; Oude Elferink RP; Beuers U
Dig Dis; 2015; 33 Suppl 2():164-75. PubMed ID: 26641452
[TBL] [Abstract][Full Text] [Related]
16. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.
Yagi M; Tanaka A; Namisaki T; Takahashi A; Abe M; Honda A; Matsuzaki Y; Ohira H; Yoshiji H; Takikawa H;
J Gastroenterol; 2018 Oct; 53(10):1151-1158. PubMed ID: 29663077
[TBL] [Abstract][Full Text] [Related]
17. New Treatment Paradigms in Primary Biliary Cholangitis.
Levy C; Manns M; Hirschfield G
Clin Gastroenterol Hepatol; 2023 Jul; 21(8):2076-2087. PubMed ID: 36809835
[TBL] [Abstract][Full Text] [Related]
18. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
[TBL] [Abstract][Full Text] [Related]
19. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Therapy of Pruritus in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Medina-Morales E; Barba Bernal R; Gerger H; Goyes D; Trivedi HD; Ferrigno B; Patwardhan V; Bonder A
J Clin Gastroenterol; 2023 Feb; 57(2):143-152. PubMed ID: 36598806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
